3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
2876
Carcinoma, Non-Small-Cell Lung
2430
Breast Neoplasms
2070
Colorectal Neoplasms
1248
Neoplasm Metastasis
1233
Prostatic Neoplasms
1083
Melanoma
973
Multiple Myeloma
963
Ovarian Neoplasms
904
Recurrence
851
Leukemia, Myeloid, Acute
809
Lung Neoplasms
759
Pancreatic Neoplasms
753
Lymphoma, Non-Hodgkin
727
Lymphoma
660
Stomach Neoplasms
624
Carcinoma, Hepatocellular
567
Carcinoma, Renal Cell
547
Squamous Cell Carcinoma of Head and Neck
529
Leukemia, Lymphocytic, Chronic, B-Cell
493
Lymphoma, Follicular
469
Head and Neck Neoplasms
452
Glioblastoma
436
Advanced Solid Tumors
433
Small Cell Lung Carcinoma
411
Triple Negative Breast Neoplasms
410
Lymphoma, Large B-Cell, Diffuse
398
Leukemia
394
Uterine Cervical Neoplasms
369
Advanced Solid Tumor
351
Interventions
abemaciclib
1
Trastuzumab
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Hormone Receptor Positive Breast Cancer
×
Clear all
NCT02675231
2024-11-26
monarcHER
Eli Lilly and Company
Phase 2
Completed
237 enrolled
25 charts